Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (661-670 of 706) with videos related to

Pageof 71
Sort By:
Population Health Management|December 4, 2024
Identifying Patients with Heart Failure Eligible for Guideline-Directed Medical TherapySamantha Subramaniam, Shahzad Hassan, Ozan Unlu, et al.
Obesity (Silver Spring, Md.)|December 19, 2024
Contemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care systemJohn W Ostrominski, Kavishwar B Wagholikar, Kelly Olsson, et al.
Journal of the American Heart Association|September 2, 2017
Self-Reported Health and Outcomes in Patients With Stable Coronary Heart DiseaseRalph A H Stewart, Emil Hagström, Claes Held, et al.
JAMA|April 5, 2008
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trialSteven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
Thrombosis Research|July 21, 2020
Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysisAntonia Sambola, Pau Rello, Toni Soriano, et al.
Diabetes, Obesity & Metabolism|March 26, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trialClare Arnott, Jing-Wei Li, Christopher P Cannon, et al.
Journal of the American Heart Association|June 23, 2016
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart DiseaseLars Wallentin, Claes Held, Paul W Armstrong, et al.
European Heart Journal|November 28, 2025
A polygenic risk score for peripheral artery disease and major adverse limb eventsSamer Al Said, Siddharth M Patel, Giorgio E M Melloni, et al.
BMJ Open Diabetes Research & Care|June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose loweringDavid M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
Critical Pathways in Cardiology|March 15, 2008
Implications of the mechanical (PCI) vs thrombolytic controversy for ST segment elevation myocardial infarction on the organization of emergency medical services: the Boston EMS experiencePeter Moyer, James Feldman, Jon Levine, et al.
Pageof 71

Showing results (661-670 of 706) with videos related to

Sort By:
Pageof 71
Population Health Management|December 4, 2024
Identifying Patients with Heart Failure Eligible for Guideline-Directed Medical TherapySamantha Subramaniam, Shahzad Hassan, Ozan Unlu, et al.
Obesity (Silver Spring, Md.)|December 19, 2024
Contemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care systemJohn W Ostrominski, Kavishwar B Wagholikar, Kelly Olsson, et al.
Journal of the American Heart Association|September 2, 2017
Self-Reported Health and Outcomes in Patients With Stable Coronary Heart DiseaseRalph A H Stewart, Emil Hagström, Claes Held, et al.
JAMA|April 5, 2008
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trialSteven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
Thrombosis Research|July 21, 2020
Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysisAntonia Sambola, Pau Rello, Toni Soriano, et al.
Diabetes, Obesity & Metabolism|March 26, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trialClare Arnott, Jing-Wei Li, Christopher P Cannon, et al.
Journal of the American Heart Association|June 23, 2016
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart DiseaseLars Wallentin, Claes Held, Paul W Armstrong, et al.
European Heart Journal|November 28, 2025
A polygenic risk score for peripheral artery disease and major adverse limb eventsSamer Al Said, Siddharth M Patel, Giorgio E M Melloni, et al.
BMJ Open Diabetes Research & Care|June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose loweringDavid M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
Critical Pathways in Cardiology|March 15, 2008
Implications of the mechanical (PCI) vs thrombolytic controversy for ST segment elevation myocardial infarction on the organization of emergency medical services: the Boston EMS experiencePeter Moyer, James Feldman, Jon Levine, et al.
Pageof 71